Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

被引：0
|
作者：
Middleton, M. R. [1 ]
Wermke, M. [2 ]
Calvo, E. [3 ]
Chartash, E. [4 ]
Zhou, H. [4 ]
Zhao, X. [4 ]
Niewel, M. [5 ]
Dobrenkov, K. [4 ]
Moreno, V. [6 ]
机构：
[1] Univ Oxford, Oncol, Oxford, England
[2] Univ Klinikum CG Carus, UCC Early Clin Trial Unit, Dresden, Germany
[3] Hosp Fdn Jimenez Diaz, Clin Res, START Madrid FJD, Madrid, Spain
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, Clin, Munich, Germany
[6] Hosp Fdn Jimenez Diaz, Med Oncol, START Madrid FJD, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY RESULTS FROM A PHASE 1/1B STUDY OF INTRATUMORAL MK-4621, A RETINOIC ACID-INDUCIBLE GENE I (RIG-I) AGONIST, PLUS INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Moreno, Victor
    Gaudy-Marqueste, Caroline
    Wermke, Martin
    Italiano, Antoine
    Romano, Emanuela
    Marabelle, Aurelien
    Connors, Emilee
    Zhou, Heng
    Dobrenkov, Konstantin
    Chartash, Elliot
    Calvo, Emiliano
    Calvo Aller, Emiliano
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A474 - A475
  • [2] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    V. Moreno
    E. Calvo
    M. R. Middleton
    F. Barlesi
    C. Gaudy-Marqueste
    A. Italiano
    E. Romano
    A. Marabelle
    E. Chartash
    K. Dobrenkov
    H. Zhou
    E. C. Connors
    Y. Zhang
    M. Wermke
    Cancer Immunology, Immunotherapy, 2022, 71 : 2985 - 2998
  • [3] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    Moreno, V
    Calvo, E.
    Middleton, M. R.
    Barlesi, F.
    Gaudy-Marqueste, C.
    Italiano, A.
    Romano, E.
    Marabelle, A.
    Chartash, E.
    Dobrenkov, K.
    Zhou, H.
    Connors, E. C.
    Zhang, Y.
    Wermke, M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (12) : 2985 - 2998
  • [4] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [5] Pathogen recognition receptors in channel catfish: II. Identification, phylogeny and expression of retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs)
    Rajendran, K. V.
    Zhang, Jiaren
    Liu, Shikai
    Peatman, Eric
    Kucuktas, Huseyin
    Wang, Xiuli
    Liu, Hong
    Wood, Theresa
    Terhune, Jeffery
    Liu, Zhanjiang
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2012, 37 (3-4): : 381 - 389
  • [6] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [7] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Retinoic acid-inducible gene I protein (RIG-I) activator Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activator Treatment of chronic hepatitis B
    Nehra, V.
    Temesgen, Z.
    DRUGS OF THE FUTURE, 2020, 45 (04) : 233 - 238
  • [9] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [10] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
12345